论文部分内容阅读
耐药和复发的何杰金氏病（HD）是否该作自体骨髓移值（ABMT）仍是颇有争议的问题。剂量强度与疗效的关系是ABMT的理论基础。本文研究了1982～1994年间有关HD挽救化疗资料中的剂量强度与疗效关系，没有得出所希望的结论。但常规化疗的结果并不满意，Ⅲ线方案的CR率仅23％。ABMT在Ⅱ线方案失败的患者中有很强适应症。
Whether anti-drug and relapsed Hodgkin’s disease (HD) should be autologous bone marrow transfer (ABMT) is still a controversial issue. The relationship between dose intensity and efficacy is the theoretical basis of ABMT. This article studied the relationship between dose intensity and efficacy in HD-recovery chemotherapy data from 1982 to 1994, and did not reach the desired conclusion. However, the results of conventional chemotherapy were not satisfactory. The CR rate of the III-line program was only 23%. ABMT has a strong indication in patients who fail in the II-line protocol.